Johnson & Johnson’s Zytiga is Forecasted to Earn Peak Year Sales of $910 Million for the Treatment of Metastatic Castrate-

Zytiga’s Primary Competition in the First-Line Asymptomatic and Minimally Symptomatic Setting Will Be Dendreon's Provenge, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Johnson & Johnson’s Zytiga will earn peak year sales of $910 million in the United States, France, Germany, Italy, Spain, United Kingdom and Japan for the treatment of metastatic castrate-resistant prostate cancer (MCRPC).

The Pharmacor findings from the topic entitled Prostate Cancer reveal that, following its recent approval by the U.S. Food and Drug Administration (FDA) for treating MCRPC patients who were previously treated with Sanofi’s Taxotere, Zytiga is also expected to launch in this same setting later this year in Europe. In a pivotal Phase III (COU-AA-302) trial, Zytiga demonstrated a survival improvement when used in combination with prednisone (3.9 months) as compared with placebo plus prednisone.

“With labeling for Zytiga as expected and mirroring the Phase III trial patient population, Zytiga will be positioned to compete with Sanofi’s cytotoxic agent Jevtana, which launched in July 2010, also for MCRPC patients who had received prior docetaxel-containing chemotherapy,” said Decision Resources Analyst Rachel Webster, D.Phil. “Zytiga’s survival benefit, coupled with its favorable safety and tolerability profile and familiar mechanism of action, will ensure that this orally available agent will experience robust uptake through 2019.”

The findings also reveal that Zytiga’s main competition in the first-line asymptomatic and minimally symptomatic setting (in which a Phase III clinical trial is ongoing) will be Dendreon's Provenge, and to a lesser extent, Active Biotech/Ipsen’s Tasquinimod. In the second- and third-line settings, Zytiga will compete primarily with Jevtana and to a lesser extent, with Takeda’s TAK-700. Both Tasquinimod and TAK-700 are currently in Phase III clinical trials in the U.S. while Provenge and Jevtana are currently available for the treatment of MCRPC.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  FDA  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.